Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Cantor Fitzgerald Adjusts Johnson & Johnson's Price Target to $200 From $180, Reiterates Overweight Rating

01/27/2021 | 09:40am EDT


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
02:01aBIOHIT OYJ : Päivi Siltala new CEO of Biohit Oyj
AQ
12:08aJOHNSON & JOHNSON : What is a COVID-19 vaccine 'breakthrough' case?
AQ
07/28JOHNSON & JOHNSON : Statement on U.S. FDA Approval of Shelf Life Extension for C..
PU
07/28JOHNSON & JOHNSON : US extends expiration dates on J&J COVID vaccine to 6 months
AQ
07/28JOHNSON & JOHNSON : Liberia Vows to Meet WHO's Benchmark As the U.S Donated Vacc..
AQ
07/28JOHNSON & JOHNSON : Aspen - STEPHEN SAAD DISCUSSES THE J&J VACCINE RELEASE WITH ..
AQ
07/28THE LATEST : CDC leader: Masks, vaccination could halt surge
AQ
07/28JOHNSON & JOHNSON : Investigation Opened Into Death of Woman After Receiving Cov..
AQ
07/28JOHNSON & JOHNSON : 'Do Not Take J & J Vaccine If You Have Taken Astrazeneca' - ..
AQ
07/28JOHNSON & JOHNSON : SA Administers Over 255 000 Jabs, Records 7 773 New Covid-19..
AQ
More news
Financials (USD)
Sales 2021 94 452 M - -
Net income 2021 22 808 M - -
Net Debt 2021 853 M - -
P/E ratio 2021 20,2x
Yield 2021 2,41%
Capitalization 453 B 453 B -
EV / Sales 2021 4,81x
EV / Sales 2022 4,59x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 172,18 $
Average target price 184,35 $
Spread / Average Target 7,07%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG11.50%329 752
PFIZER, INC.18.04%235 663
NOVARTIS AG-0.44%221 987
ELI LILLY AND COMPANY46.00%221 420
ABBVIE INC.10.64%208 344